Post on 30-Dec-2015
description
transcript
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCES
Oracle’s position in the Life Sciences Industry
Charles Scatchard, Vice President Healthcare and Life Sciences EMEA
Oracle France Pharma Day
Paris, October 13th, 2005
2
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESThe LS value chain
Patients
Suppliers Payers / Regulators
Pharmaceutical
Medical Eqpt
Integrated
Networks
Hospitals
PrimaryCare
Outpatient
Other
Biotech
Distributor/Wholesaler
Regulatory
Agency
Physicians
Payer
Employer
Providers
Retailer
Discovery
Pharmaceutical Mfg Plant
Development
Manufacturing, Salesand Marketing Hospital
Pharmacy
Distribution
Biotech /PharmaceuticalResearch Labs
Wet Lab
In Silico
Contract Research Organization
PharmaceuticalCompany
RegulatoryAgency
Clinical T
rials
Clinical T
rials
BiomedicalFirm
BiomedicalFirm
PharmaceuticalCompany
Pre-Clinical T
rials
Pre-Clinical T
rials
Public/Private Data
SampleData
3
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCES… is completely covered by Oracle
Discovery• High performance GRID computing• BLAST Algorithm and other Search Tools
Development• Oracle Pharmaceutical Application (OPA) suite: Clinical Data
Management & Remote Data Capture, Thesaurus Management, Adverse Events Reporting, Clinical Trials Management
Manufacturing, Sales and Marketing• CRF part 11 compliant Manufacturing• ERP (Financial, HR, Procurement)• Customer Relationship Management
Common foundation• Technology stack (performance, scalability, security, etc.)• Data structures• Business Intelligence and Data Warehousing
4
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESOracle LS footprint
28 of top 30 pharma • Pfizer, GlaxoSmithKline, Merck, Johnson & Johnson, Sanofi-Aventis, AstraZeneca,
Novartis, Bristol-Myers Squibb, Wyeth, Eli Lilly, Abbott Labs, Roche, Boehringer Ingelheim, Amgen, Takeda, Schering-Plough, Schering AG, Bayer, Sankyo, Yamanouchi, Novo Nordisk, Merck KGaA, Teva, Baxter, Akzo Nobel, Fujisawa, Genentech
75% of CROs
20 research organizations • incl. National Cancer Institute
16 of top 20 Medical Device• Johnson and Johnson, GE Medical Systems, Baxter International, Tyco Healthcare,
Medtronic, Philips Medical Systems, Roche Diagnostics, Abbott Laboratories, Guidant, Stryker, B. Braun, Boston Scientific, Becton, Dickinson & Co., Cardinal Health, Smith & Nephew
5
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESOPA seen by independent research
6
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESConvergence of HC & LS
What we are seeing?• Convergence of standards• Frustration with or lack of data re-use • Personalized medicine• Life Sciences focus on disease management• Emerging eHealth initiatives worldwide
- Brailer initiative, NHIN, UK (National Spine), Sweden, etc.
Why is important?• Traditional data capture and EDC haven’t realized full potential
benefits: process is still inherently inefficient
7
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESConvergence of HC & LS
How are we helping our customers?• Driving the standards (HL7/CDISC)
- Integrate clinical applications with healthcare solutions• Real time clinical information• Single data capture• Working with strategic partners who share of “patient-centric”
approach to clinical data management- Data integration for drug discovery- Cohort identification- Future: Controls re-use in multiple studies
8
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESLong-term strategy: Revolution
Complete migration of all HC and LS applications (Project Fusion)• Process flows through entire suite
• Harmonization of all Pharma (OPA) and HC (HTB) data models
Focus on Business Intelligence• Patient-centric data
• Product Lifecycle Management
Translational Research• Semantic Web (RDF) as basis of Knowledge management
Driving Healthcare – Life Sciences convergence
9
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCES
AQ&Q U E S T I O N S
A N S W E R S
10
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCES
11
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESUNUSED / BACKUP
12
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCES
IncreaseStakeholder
Value
Strategic imperatives in LS
Decreasing R&D productivity and
expiration of blockbuster patents
Pressure in health systems to reduce cost of care and
increase patient safety
Less well understood disease mechanisms on the basis of Genomic /
Proteomic research
Sustain Innovation Increase productivity in R&D Capitalize on internal and external information
Manage Risk Ensure patient safety Manage compliance
Increase profitability Sustain top line growth Reduce costs
Oracle’s approach
13
HEALTHCARE and LIFE SCIENCESHEALTHCARE and LIFE SCIENCESLS/HC platform: Long range vision
E-Business Data Repository
Healthcare Data
Repository
IntegrationEngine
Standards BasedMessaging
Clinical Systems
ResearchSystems
E-BusinessSuite
Healthcare Transaction Base
Clinical Trails
ResearchApplications